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Abstract
Background: Trachoma, an infectious disease of the conjunctiva caused by Chlamydia trachomatis,
is an important global cause of blindness. A dysregulated extracellular matrix (ECM) proteolysis
during the processes of tissue repair following infection and inflammation are thought to play a key
role in the development of fibrotic sequelae of infection, which ultimately leads to blindness.
Expression and activity of matrix metalloproteinase 9 (MMP-9), a major effector of ECM turnover,
is up-regulated in the inflamed conjunctiva of trachoma subjects. Genetic variation within the MMP9
gene affects in vitro MMP9 expression levels, enzymatic activity and susceptibility to various
inflammatory and fibrotic conditions.
Methods: We genotyped 651 case-control pairs from trachoma endemic villages in The Gambia
for coding single nucleotide polymorphisms (SNPs) in the MMP9 gene using the high-throughput
Sequenom® system. Single marker and haplotype conditional logistic regression (CLR) analysis for
disease association was performed.
Results: The Q279R mutation located in exon 6 of MMP9 was found to be associated with lower
risk for severe disease sequelae of ocular Chlamydia trachomatis infection. This mutation, which
leads to a nonsynonymous amino-acid change within the active site of the enzyme may reduce
MMP-9-induced degradation of the structural components of the ECM during inflammatory
episodes in trachoma and its associated fibrosis.
Conclusion: This work supports the hypothesis that MMP-9 has a role in the pathogenesis of
blinding trachoma.
Background
Trachoma, a chronic keratoconjunctivitis caused by
Chlamydia trachomatis, is the commonest infectious cause
of blindness. The blinding complications of trachoma are
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due to progressive scarring of the conjunctiva (trachoma-
tous scarring) eventually leading to in-turning of eye-
lashes (trichiasis) and corneal opacification. Genital C.
trachomatis infection causes similar lesions in the female
genital tract contributing to ectopic pregnancy and infer-
tility. Severe and persistent inflammation triggered by
repeated conjunctival infections is believed to increase the
risk of pathological scarring later in life[1].
The mechanisms of disease pathology are not completely
understood. Some evidence suggests that the dysregulated
ECM proteolysis seen during the processes of tissue repair
following infection and inflammation [2] may play a key
role in the development of fibrotic sequelae of chlamydial
infection in humans. In support of this hypothesis, we
have recently shown that ocular C. trachomatis infection
upregulates the expression of MMP-9 in the human con-
junctival epithelium [3]. MMP-9 activity has been
detected in immune cells present in the inflammatory
infiltrate in conjunctival biopsy specimens from individu-
als with active trachoma [4]. In addition recent compara-
tive studies of the role of MMP-9 in genital Chlamydia
muridarum (MoPn) infection found greater MMP-9 tran-
scription and activity during infection in those mouse
strains exhibiting increased susceptibility to fibrotic
sequelae following infection [5,6].
Matrix metalloproteinases (MMPs) are a tightly regulated
family of zinc-dependent enzymes that degrade structural
proteins of the ECM and basement membranes. Among
them, MMP-9 is a major effector of ECM turnover during
homeostasis and pathology [7]. MMP9 expression is regu-
lated at the transcriptional level in response to pro-
inflammatory cytokines such as tumor necrosis factor
(TNF) and interleukin 1 beta (IL-1β) [8]. Post-transcrip-
tional regulation also occurs by control of activation of
the secreted pro-enzyme (proMMP-9), and inhibition of
proMMP-9 and MMP-9 by tissue inhibitors (TIMPs) [7].
A number of SNPs have been identified in regulatory and
coding regions of the MMP9 gene. Some of them have
been reported to affect in vitro MMP9 expression levels,
enzymatic activity and susceptibility to various inflamma-
tory and fibrotic conditions [9]. We tested the hypothesis
that genetic variation in coding regions of MMP9 affects
the risk of scarring sequelae of trachoma.
Methods
Patients
One thousand three hundred and fifteen subjects identi-
fied by clinical examination using World Health Organi-
zation (WHO) criteria were recruited from trachoma
endemic villages in The Gambia. They included 651 sub-
jects with scarring trachoma (TS), of whom 307 addition-
ally had trichiasis (TT), and pair-matched by sex, age,
ethnic group and village of residence individuals with
normal eyelids. The subjects were otherwise healthy. We
have previously studied and reported polymorphism at
the IFNγ and IL10 loci in these subjects [10]. The study
and its procedures were approved by the Gambia Govern-
ment/MRC Ethics Committee (SCC 729/857), the Ethics
committees of the London School of Hygiene and Tropi-
cal Medicine and of Oxford University, and are in accord-
ance with the Declaration of Helsinki. Subjects diagnosed
with trichiasis were offered free corrective surgery.
DNA extraction and SNP genotyping
Genomic DNA was isolated from either venous blood in
EDTA or buccal brush samples and genotypes were deter-
mined by the Sequenom® system as previously described
[10]. Primer sequences are available on request.
Analytical methods
Haplotype reconstruction and frequencies
Haplotypes were inferred from population genotype data
and their frequencies were estimated as previously
described [10].
Association analysis
A crude analysis (crude Mantel-Haenzsel) was first carried
out using chi-square testing to test for differences in allele
and haplotype frequencies between cases of TS and TT
with their pair-matched controls. In addition, conditional
logistic regression (CLR) analysis for disease association
was performed. Conditional logistic regression is the anal-
ysis of choice for dichotomous paired data (in our case
paired cases and controls) where the risk estimates associ-
ated with specific attributes (e.g genotype) are required to
be adjusted for potential confounders. Reference geno-
types were selected to be those that were common in our
study population. A CLR test for trend in the odds ratios
(OR) was performed to examine dose response effects in
the relationship between genotype and disease. All analy-
ses were performed using STATA (v8.0) software.
Results
Single-marker analysis
A total of four exonic SNPs of population frequency >
10% were typed at the MMP9 locus (Figure 1). The distri-
bution of all marker genotypes among cases and controls
were in Hardy-Weinberg equilibrium (data not shown).
Table 1 shows the genotype frequencies at each locus for
each phenotype and the results of CLR association analy-
sis of matched case-control pairs. The Q279R G allele fre-
quency was marginally higher among controls than
scarred subjects (0.31 vs 0.27, OR = 0.854, 95%CI =
0.714, 1.021, p = 0.083). The Q279R G allele was present
in 45.1% of TS subjects against 51.6% of controls, and in
38.7% of TT subjects compared to 52.0% of controls. In
adjusted analysis, presence of the Q279R G allele wasBMC Medical Genetics 2006, 7:40 http://www.biomedcentral.com/1471-2350/7/40
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associated with a reduced risk of TS (OR = 0.74, 95%CI =
0.59, 0.94, p = 0.012), and with a greater decrease in risk
for the more severe TT phenotype (OR = 0.66, 95%CI =
0.46, 0.94, p = 0.021). Although there was some evidence
for a trend towards decreasing risk of TS and TT with
increasing number of Q279R G alleles, it did not reach
statistical significance (OR = 0.864, 95%CI = 0.727, 1.027
and OR = 0.832, 95%CI = 0.644, 1.074 for TS and TT
respectively). Heterozygotes Q279R AG were at lower risk
of both TS and TT (OR = 0.69, 95%CI = 0.54, 0.81, p =
0.004 and OR = 0.57, 95%CI = 0.38, 0.85 p = 0.006
respectively) (data in Table 1).
Haplotype analysis
Table 2 shows the estimated frequency and associated
risks of TS and TT by multivariate CLR analysis for inferred
haplotypes at the MMP9 locus spanning exons 6 to 13.
The 4 SNP sites segregated into seven haplotypes. Four
common haplotypes with population frequency > 10%
accounted for more than 80% of total variation, suggest-
ing high linkage disequilibrium (LD) between segregating
sites.
The GCAG haplotype was associated with lower risk of TS
and TT (Table 2). The risk of both TS and TT decreased
with the number of copies of the haplotype GCAG (test
for trend OR = 0.81, 95%CI = 0.63, 1.02, p = 0.07 and OR
= 0.67 95%CI = 0.46, 0.96, p = 0.03 for TS and TT respec-
tively). The GCAG-haplotype effect on risk of TT was
greater than that on risk of TS.
Haplotypes containing the Q279R G allele, itself associ-
ated with decreased risk, were more commonly seen
among controls than cases, although the difference in
haplotype frequency between cases and controls reach sig-
nificance only for haplotype GCAG. Conversely, the com-
monest haplotypes ACCG and ACAG were more
frequently seen among cases than controls, and both carry
the Q279R A allele. The strength of the single marker asso-
ciation is very similar to, if not greater than that of the
haplotype, which supports the suggestion that the Q279R
SNP itself may be causal.
Discussion
The present study found a coding SNP (Q279R in exon 6)
within the MMP9 gene to be associated with a lowered
risk of trachomatous scarring and trichiasis, which was
Diagram showing genotyped SNPs labelled according to the amino acid position Figure 1
Diagram showing genotyped SNPs labelled according to the amino acid position.
dbSNP Chromosomal Amino  acid Alleles Function
reference
a coordinate
b  position scarred controls
cases
rs2664538 44073632 Q279R (exon 6) A→G nonsynonymous change 0.27 0.31
rs2250889 44075813 R574P (exon 10) C→G nonsynonymous change 0.15 0.15
rs13969 44076240 G607G (exon 11) A→C synonymous change 0.42 0.41




 b coordinate in chromosome 20q11.2-
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more marked for trichiasis. This supports the validity of
the association because trichiasis is a more advanced form
of cicatricial trachoma and also less subject to clinical mis-
classification than scarring trachoma.
The Q279R mutation leads to the substitution of a posi-
tively charged amino-acid (arginine) by an uncharged
amino acid (glutamine) at position 279 within the MMP9
active site. Although the functional impact of this poly-
morphism on the protein is unknown, this variant is note-
worthy; it is located in the coding sequence of one of the
highly conserved fibronectin type II-like repeats which
confers MMP-9 with high affinity binding to type IV colla-
gen, type I gelatin and elastin [11,12]. The digestion of
type IV collagen in the epithelial basement membrane has
been suggested to be a key regulatory event in the initia-
tion of fibrosis. A plausible explanation of these results is
that Q279R represents a partial loss-of-function mutation
Table 1: Genotype frequencies for the polymorphisms at the MMP9 locus in the study population and risk estimates from CLR analysis 
of matched case-control pairs.
Polymorphisms at the MMP9 locus in the study population
Genotype # of genotype (freq) crude M-H 
OR(95%CI)
CLR-OR (95%CI) P value
Scarring cases (TS) controls
Q279R AA 330(0.55) 311(0.48) 1.18 (1.00, 1.38) reference -
Q279R AG 209(0.35) 270(0.42) 0.80 (0.67, 0.96) 0.70(0.54, 0.89) 0.004
Q279R GG 62(0.10) 61(0.10) 1.07 (0.74, 1.55) 0.95(0.64,1.41) 0.805
R574P CC 450(0.73) 459(0.72) 0.98 (0.86, 1.12) reference -
R574P CG 155(0.25) 161(0.25) 0.96 (0.77, 1.20) 0.97(0.74, 1.28) 0.845
R574P GG 15(0.02) 14(0.02) 1.07 (0.52, 2.22) 1.07(0.50, 2.28) 0.857
G607G AA 204(0.35) 193(0.35) 1.06 (0.87, 1.29) reference -
G607G AC 265(0.46) 268(0.48) 0.99 (0.83, 1.17) 0.91(0.68, 1.22) 0.538
G607G CC 114(0.20) 94(0.17) 1.21 (0.92, 1.59) 1.06(0.73, 1.55) 0.746
V694V GA 453(0.75) 443(0.74) 1.02 (0.90, 1.17) reference -
V694V GG 138(0.23) 145(0.24) 0.95 (0.75, 1.20) 0.94(0.71, 1.26) 0.694
V694V AA 14(0.02) 11(0.02) 1.27 (0.58, 2.80) 1.11 (0.49, 2.48) 0.807
Risk estimates from CLR analysis of matched case-control pairs
Q279R AA 166(0.61) 131(0.48) 1.28 (1.01, 1.59) reference -
Q279R AG 75(0.28) 117(0.43) 0.64 (0.48, 0.86) 0.57 (0.38, 0.85) 0.006
Q279R GG 30(0.11) 25(0.11) 1.20 (0.71, 2.04) 0.95 (0.54, 1.69) 0.945
R574P CC 218(0.74) 213(0.71) 1.02 (0.85, 1.24) reference -
R574P CG 68(0.23) 80(0.27) 0.85 (0.62, 1.17) 0.76(0.50, 1.14) 0.181
R574P GG 7(0.02) 7(0.02) 1.00 (0.35, 2.85) 1.06(0.31–3.69) 0.927
G607G AA 97(0.35) 101(0.37) 0.96 (0.73, 1.27) reference -
G607G AC 127(0.46) 132(0.48) 0.96 (0.75, 1.23) 0.96(0.63, 1.46) 0.851
G607G CC 55(0.20) 43(0.16) 1.28 (0.86, 1.91) 1.03(0.60, 1.78) 0.908
V694V GA 225(0.79) 213(0.76) 1.06 (0.88, 1.27) reference -
V694V GG 54(0.19) 63(0.22) 0.86 (0.60, 1.23) 0.94(0.60, 1.48) 0.371
V694V AA 5(0.02) 5(0.02) 1.00 (0.29, 3.45) 0.79 (0.21, 2.95) 0.725BMC Medical Genetics 2006, 7:40 http://www.biomedcentral.com/1471-2350/7/40
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within the proteinase whose presence reduces the devel-
opment of fibrosis; these findings implicate MMP-9 as a
key molecule in the pathogenesis of conjunctival scarring
in trachoma.
The effect observed in this work was primarily associated
with the Q279R GA heterozygous genotype. It is possible
that the apparent lack of statistical effect of the GG
homozygous genotype may have resulted from the mod-
est sample size within the Q279R GG stratum. However
we do not rule out the possibility of this finding being
genuine and of biological significance; the increased risk
of cicatricial trachoma associated with the Q279R AA
homozygous genotype may be linked to the excessive
MMP-9-driven proteolytic activation seen in the chronic
inflammatory environment of the conjunctiva of subjects
with trachoma[3,4]. Conversely, if Q279R GG homozy-
gotes secrete only "sub-functional" copies of the enzyme,
associated with low MMP-9 activity, this may result in dis-
ordered tissue remodelling because of a greater deposition
of matrix, which has been found to correlate with hyper-
trophic scars[13]. In this setting, an advantage for Q279R
GA heterozygotes could arise from the secretion of both
native and defective forms of the enzyme at the site of
inflammation upon cellular activation. This may lead to
both a reduction of tissue proteolysis in chronic inflam-
mation and protection against excessive tissue destruction
and scarring.
MMP-9 expression and activity is up-regulated in the
inflamed conjunctiva of trachoma subjects and increases
with the severity of clinical inflammation [3,4]. There is
evidence to suggest that the elevated local levels of TNF
and IL-1β associated with chlamydial infection and
inflammation[3] act as an important trigger of matrix deg-
radation by inducing MMP-9 activity in inflamed tissue.
Destruction of the ECM may facilitate cell migration and
result in the characteristic infiltrating leukocytes and stro-
mal cells (e.g. macrophages and fibroblasts) seen in tra-
choma subjects[4]. The secretion of MMP-9, cytokines
and chemokines by these cells may drive the inflamma-
tory process into a positive feedback loop. MMP-9 can
activate pro-inflammatory cytokines[14] which may fur-
ther increase and perpetuate inflammation leading to per-
sistent tissue damage. Later during the tissue repair phase,
excessive MMP activities may contribute to contractile
scarring, characteristic of TS and TT, through their role in
ocular fibroblast-mediated matrix contraction [15,16]. It
is plausible that persistently increased MMP9 activity in
the conjunctiva of subjects with trachoma may be a key
event in the pathogenesis of conjunctival scarring through
excessive degradation of ECM and fibrosis. The recent
characterisation of MMP-9 expression and activity in
mouse strains exhibiting variable susceptibility to seque-
lae of genital Chlamydia muridarum (MoPn) infection[5]
supports this suggestion: C3H/HeN mice, which are par-
ticularly susceptible to fibrotic sequelae in this model[6],
exhibited greater MMP-9 transcription and activity during
infection.
The blinding lesion in trachoma is corneal opacity (CO),
which is thought to result from the lashes rubbing against
the eyeball (TT) and damaging the cornea. Epidemiologi-
cal studies indicate that after successful TT surgery, CO can
develop[17], and there is evidence that inflammatory epi-
sodes in TT subjects correlate with the presence of CO[15].
MMPs are expressed at sites of epithelial loss in ulcerated
corneas and found in the tear film of patients with exter-
nal ocular inflammatory disorders[18]. In the cornea, an
imbalance in MMP9 production has been implicated in
corneal scarring and loss of corneal transparency and vis-
ual function[7]. Proteolytic destruction of the glandular
tissue contributes to reduced secretion of tears, and is
associated with a number of corneal pathologies[7]. The
constant exposure of the corneal surface to conjunctival
and/or tear MMP-9 and inflammatory cytokines may con-
tribute to progressive corneal opacification. CO may be a
relevant phenotype for MMP9 genetic association analy-
sis, but for practical reasons large numbers of patients
with CO are difficult to come by.
Conclusion
This work supports the hypothesis that MMP-9 has a role
in the pathogenesis of blinding trachoma. The risk reduc-
tions associated with the Q279R exonic mutation are
modest: 26% for scarring and 34% for trichiasis. CLR
Table 2: Comparison of MMP9 haplotype frequency estimates in cases and controls and risk estimates from CLR analysis of matched 
case-control pairs. The haplotype configuration is as follows: Q279R, R574P, G607G and V694V.
haplotype # controls freq # cases (TS) freq p-value CLR:OR (95%CI) # controls freq # cases(TT) freq p-value CLR:OR (95%CI)
ACCG 450 0.34 466 0.36 - reference 204 0.32 218 0.36 - reference
ACAG 298 0.22 303 0.23 0.845 0.98(0.80, 1.21) 150 0.24 167 0.27 0.514 1.11 (0.82, 1.50)
GCAA 201 0.15 186 0.14 0.257 0.87 (0.69, 1.11) 91 0.14 75 0.12 0.224 0.79 (0.54, 1.15)
GCAG 161 0.12 130 0.10 0.048 0.77 (0.59, 0.99) 80 0.13 55 0.09 0.021 0.62 (0.41, 0.93)
AGAG 123 0.09 130 0.10 0.705 1.06 (0.79,1.40) 61 0.10 55 0.09 0.451 0.85 (0.56, 1.30)
AGCG 66 0.05 55 0.04 0.204 0.78 (0.53, 1.15) 33 0.05 27 0.04 0.171 0.66 (0.37, 1.20)
GCCG 30 0.02 32 0.02 0.977 0.99 (0.58, 1.68) 13 0.02 17 0.03 0.604 1.24 (0.56, 2.75)Publish with BioMed Central    and   every 
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analysis suggests that these effects are independent of
those previously reported in the interleukin 10 (IL10) and
interferon gamma (IFNγ) loci [10]. This is consistent with
a model of cicatricial trachoma as a complex disorder with
multiple genetic factors contributing to risk of scarring
and trichiasis after ocular chlamydial infection. Further
studies of MMP-9 in chlamydial infection and of the func-
tional significance of genetic variation at the MMP-9
locus, are warranted.
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